It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibits cell wall synthesis, binds to peptidoglycan, inhibits the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and shows a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative rods, and has good antibacterial activity against the following bacteria in vitro: 1. Most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae, and Moraxella. 2. It has antibacterial activity against most strains of Pseudomonas, such as Pseudomonas aeruginosa. 3. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus, and Enterococcus faecalis. It has good antimicrobial effects against Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. 4. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. The drug resistance of this product is currently increasing, and there is cross-resistance with other quinolones.

This product is a broad-spectrum antiviral drug. Its mechanism of action is mainly to inhibit inosine dehydrogenase, block the conversion of inosine-phosphate to xanthine-phosphate, thereby inhibiting nucleic acid synthesis and preventing viral replication.

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.